Showing results (231-240 of 251) with videos related to

Sort By:
Pageof 26
International Journal of Clinical Oncology|January 6, 2024
Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencingKazushige Wakuda, Meiko Morita, Motoki Sekikawa, et al.
Investigational New Drugs|October 30, 2021
Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysisKosei Doshita, Hirotsugu Kenmotsu, Shota Omori, et al.
Respiratory Investigation|July 19, 2025
Association of FDG-PET/CT findings with adequate tissue samples for gene panel testing in transbronchial lung biopsy and endobronchial ultrasound-guided transbronchial needle aspirationAkiko Tamura, Ryo Ko, Hirotsugu Kenmotsu, et al.
The Oncologist|April 17, 2020
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401Eiji Iwama, Yasushi Goto, Haruyasu Murakami, et al.
Plos One|July 11, 2013
Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array systemMasahito Hosokawa, Hirotsugu Kenmotsu, Yasuhiro Koh, et al.
Thoracic Cancer|June 13, 2022
Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancerTaichi Miyawaki, Tateaki Naito, Kosei Doshita, et al.
Cancer Treatment and Research Communications|March 30, 2025
Deterioration of performance status before administration of chemotherapy as a prognostic factor in untreated advanced non-small cell lung cancerKenju Ando, Hirotsugu Kenmotsu, Yuichiro Nishibori, et al.
JTO Clinical and Research Reports|October 10, 2025
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER StudyByoung Chul Cho, Myung-Ju Ahn, Makoto Nishio, et al.
Cancer Treatment and Research Communications|November 13, 2024
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective studyYuichiro Nishibori, Hirotsugu Kenmotsu, Kenju Ando, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108LYoshiko Urata, Nobuyuki Katakami, Satoshi Morita, et al.
Pageof 26